How effective is natalizumab induction therapy in patients with Crohn's disease? Commentary

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 5, Issue 2, 2008, Pages 78-79

  Fellermann, Klaus ^a   Stange, Eduard F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; NATALIZUMAB; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; ENTERITIS; HUMAN; INFECTION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; REMISSION; RHINOPHARYNGITIS; SHORT FORM 36; SHORT SURVEY;

EID: 39049162820     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1031     Document Type: Short Survey

References (5)

1. Ghosh S et al. (2003) Natalizumab for active Crohn's disease. N Engl J Med 348: 24-32
2. Sandborn WJ et al. (2004) Natalizumab induction and maintenance therapy for Grohn's disease. N Engl J Med 353: 1912-1925
3. Van Assche G et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368
4. Fellermann K et al. (2003) Crohn's disease: A defensin deficiency syndrome? Eur J Gastroenterol Hepatol 15: 627-634
5. Wehkamp J et al. (2005) Mechanisms of disease: Defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2: 406-415